RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma

Molecular Cancer Therapeutics

Volumn 13, Issue 12, 2014, Pages 3049-3061

  Yeom, Seon Yong ^a   Nam, Do Hyun ^a   Park, Chaehwa ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; STEM CELL FACTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR NANOG; ALKYLATING AGENT; DACARBAZINE; RAS PROTEIN; RRAD PROTEIN, HUMAN;

ARTICLE; ASTROCYTOMA; CARCINOGENESIS; CELL NUCLEUS; ENDOSOME; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SURVIVAL; ANALOGS AND DERIVATIVES; CELL TRANSFORMATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; PATHOLOGY; PROGNOSIS; PROTEIN TRANSPORT; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; ENDOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; PROGNOSIS; PROTEIN STABILITY; PROTEIN TRANSPORT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84918550394     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0244     Document Type: Article

References (48)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
3. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
4. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17:362-75.
5. Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, et al. TGF-β receptor inhibitors target the CD44(high)/Id1 (high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010;18:655-68.
6. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012;14:150-8.
7. Lo HW, Cao W, Zhu H, Ali-Osamn F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in highgrade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 2008;14:6042-54.
8. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27:2383-92.
9. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGFreceptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-8.
10. Bild AH, Turkson J, Jove R. Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J 2002;21:3255-63.
11. Reynet C, Kahn CR. Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. Science 1993;262:1441-4.
12. Bilan PJ, Moyers JS, Kahn CR. The Ras-related protein Rad associates with the cytoskeleton in a non lipid-dependent manner. Exp Cell Res 1998;242:391-400.
13. Moyers JS, Bilan PJ, Zhu J, Kahn CR. Rad, and Rad-related GTPases interact with calmodulin and calmodulin-dependent protein kinase II. J Biol Chem 1997;272:11832-9.
14. Zhu J, Bilan PJ, Moyers JS, Antonetti DA, Kahn CR. Rad, a novel rasrelated GTPase, interacts with skeletal muscle b-tropomyosin. J Biol Chem 1996;271:768-73.
15. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
16. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004;108:467-70.
17. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
18. Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA. Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer 2009;45:1294-303.
19. Maresch J, Birner P, Zakharinov M, Toumangelova-Uzeir K, Natchev S, Guentchev M. Additive effect on survival of Raf kinase inhibitor protein and signal transducer and activator of transcription 3 in high-grade glioma. Cancer 2011;117:2499-504.
20. Tseng YH, Vicent D, Zhu J, Niu Y,Adeyinka A, Moyers JS, et al.Regulation of growth and tumorigenicity of breast cancer cells by the lowmolecular weight GTPase Rad and nm23. Cancer Res 2001;61:2071-9.
21. Lee I, Yeom SY, Lee SJ, Kang WK, Park C. A novel senescenceevasion mechanism involving Grap2 and Cyclin D interacting protein inactivation by Ras associated with diabetes in cancer cells under doxorubicin treatment. Cancer Res 2010;70:4357-65.
22. Yeom SY, Lee SJ, Kim WS, Park C. Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. Leukemia Res 2012;36:1172-8.
23. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB,et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012;14:670-7.
24. Wang SC, Hung MC. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res 2009;15:6484-9.
25. Wang YN, Yamaguchi H, Huo L, Du Y, Lee HJ, Lee HH, et al. The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem 2010;285:38720-9.
26. Wang H, Li S, Li H, Li C, Guan K, Luo G, et al. SGEF enhances EGFR stability through delayed EGFR trafficking from early to late endosomes. Carcinogenesis 2013;34:1976-83.
27. Sato K, Nagao T, Iwasaki T, Nishihira Y, Fukami Y. Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells. Genes Cells 2003;8:995-1003.
28. Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C, Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 2006;10:839-50.
29. de la Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med 2009;9:580-90.
30. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
31. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
32. Fong H, Hohenstein KA, Donovan PJ. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 2008;26:1931-8.
33. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
34. Yoshida T, Matsuda Y, Naito Z, Ishiwata T. CD44 in human glioma correlates with hitopathological grade and cell migration. Pathol Int 2012;62:463-70.
35. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 2009;7:989-99.
36. Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010;12:756-60.
37. Nakahata AM, Suzuki DE, Rodini CO, Pereira MC, Janjoppi L, Okamoto OK.Human glioblastoma cells display mesenchymal stem cell features and form intracranial tumors in immunocompetent rats. J Stem Cells 2010;5:103-11.
38. Dick JE. Stem cell concepts renew cancer research. Blood 2008;112:4793-807.
39. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23.
40. Kang J, Shakya A, Tantin D. Stem cells, stress, metabolismand cancer: a drama in two Octs. Trends Biochem Sci 2009;34:491-9.
41. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 2012;31:4898-911.
42. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007;67:9066-76.
43. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.
44. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-5.
45. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96.
46. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-70.
47. Shinohara ET, Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Curr Mol Med 2009;9:1034-45.
48. Xia C, Bao Z, Tabassam F. GCIP, a novel human grap2 and cyclin D interacting protein, regulates E2F-mediated transcriptional activity. J Biol Chem 2000;275:20942-8.